GlobeNewswire: Pivot Pharmaceuticals Inc. Contains the last 10 of 21 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T04:52:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/03/12/1420246/0/en/Pivot-Pharma-Retains-Cannabis-Compliance-to-File-Dealer-s-License-Application-on-Behalf-of-Agro-Biotech-Inc.html?f=22&fvtc=4&fvtv=43267Pivot Pharma Retains Cannabis Compliance to File Dealer’s License Application on Behalf of Agro-Biotech Inc.2018-03-12T07:30:00Z<![CDATA[Dr. Wolfgang Renz Appointed Pivot’s Chief Medical Officer Dr. Wolfgang Renz Appointed Pivot’s Chief Medical Officer]]>https://www.globenewswire.com/news-release/2018/03/06/1415916/0/en/Pivot-Pharma-Acquires-Thrudermic-LLC.html?f=22&fvtc=4&fvtv=43267Pivot Pharma Acquires Thrudermic, LLC2018-03-06T14:13:10Z<![CDATA[VANCOUVER, British Columbia, March 06, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”) is pleased to announce the acquisition of Thrudermic, LLC (“TDL” or “Thrudermic”), a privately held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr. Borovsky, has been appointed Pivot’s Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director, Product Formulation.]]>https://www.globenewswire.com/news-release/2018/03/05/1414835/0/en/Pivot-Pharma-Closes-C-5M-Private-Placement-of-Convertible-Debentures.html?f=22&fvtc=4&fvtv=43267Pivot Pharma Closes C$5M Private Placement of Convertible Debentures2018-03-05T13:00:00Z<![CDATA[VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB: PVOTF) (“Pivot” or the “Company”) is pleased to announce the closing of its previously announced private placement of convertible debentures for aggregate gross proceeds of C$5 million (the “Offering”). The Company intends to use the net proceeds of the Offering for the development of its pipeline of products, intellectual property acquisitions, and for working capital and general corporate purposes.]]>https://www.globenewswire.com/news-release/2018/02/27/1396145/0/en/Pivot-Pharma-Completes-Acquisition-of-California-Based-ERS-Holdings-LLC.html?f=22&fvtc=4&fvtv=43267Pivot Pharma Completes Acquisition of California-Based ERS Holdings, LLC2018-02-27T14:29:51Z<![CDATA[Announces C$5M Private Placement of Convertible Debentures from Institutional Investor Announces C$5M Private Placement of Convertible Debentures from Institutional Investor]]>https://www.globenewswire.com/news-release/2018/02/22/1380359/0/en/Pivot-Pharma-Announces-Letter-of-Intent-for-Proposed-Acquisition-of-Agro-Biotech-a-Qu%C3%A9bec-based-ACMPR-Licensed-Producer.html?f=22&fvtc=4&fvtv=43267Pivot Pharma Announces Letter of Intent for Proposed Acquisition of Agro-Biotech, a Québec-based ACMPR Licensed Producer2018-02-22T22:48:47Z<![CDATA[Production of 10,000 kg of Dried Cannabis Annually at Full Capacity Production of 10,000 kg of Dried Cannabis Annually at Full Capacity]]>https://www.globenewswire.com/news-release/2018/02/13/1340170/0/en/Pivot-Provides-Market-Activity-Update.html?f=22&fvtc=4&fvtv=43267Pivot Provides Market Activity Update2018-02-13T20:09:58Z<![CDATA[VANCOUVER, British Columbia, Feb. 13, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, wishes to to address the recent decline in its share price.]]>https://www.globenewswire.com/news-release/2018/02/12/1338818/0/en/Pivot-Pharmaceuticals-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=43267Pivot Pharmaceuticals Provides Corporate Update2018-02-12T09:00:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, is pleased to provide its shareholders with the following Corporate Update.]]>https://www.globenewswire.com/news-release/2018/02/01/1329820/0/en/Pivot-Files-Three-New-Provisional-Patents-for-the-Delivery-of-Cannabinoids.html?f=22&fvtc=4&fvtv=43267Pivot Files Three New Provisional Patents for the Delivery of Cannabinoids2018-02-01T09:00:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), is pleased to announce that it has filed three provisional patents with the United States Patent and Trademark Office (“USPTO”) related to the delivery of cannabinoid-based products. The applications cover the following areas:]]>https://www.globenewswire.com/news-release/2018/01/17/1295539/0/en/Pivot-Continues-To-Build-Technology-Portfolio.html?f=22&fvtc=4&fvtv=43267Pivot Continues To Build Technology Portfolio2018-01-17T09:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), are pleased to provide its shareholders with a Corporate Update.]]>https://www.globenewswire.com/news-release/2018/01/09/1285849/0/en/Pivot-To-Initiate-Topical-Product-Development-With-Israel-Based-Research-Organizations.html?f=22&fvtc=4&fvtv=43267Pivot To Initiate Topical Product Development With Israel Based Research Organizations2018-01-09T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- via Network NewsWire -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), are pleased to announce that the Company has signed a Service Agreement with SoluBest Ltd., an Israeli-based research organization that specializes in the development of client tailored formulation and pilot production services and scale-up. SoluBest, located near the prestigious Weizmann Institute of Science, has been selected to develop Pivot’s topical bio-cannabis pipeline of products.]]>